| Similar Articles |
|---|
 |
Chemistry World
August 20, 2009
Sarah Houlton |
Testing times: predicting hep C response A finding by David Goldstein and his group at Duke University in the US may make it possible to predict which patients are likely to benefit from the drugs, and which will probably suffer the nasty side-effects without much chance of success.   |
The Motley Fool
October 30, 2006
Brian Lawler |
Vertex's Healthy Trial Results Shares of the pharmaceutical company were up on the release of positive clinical trial data. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Hepatitis C: Another Protease Revolution The launch of a new class of protease inhibitors is set to transform HCV treatment over the next decade, with kinder, gentler oral antiviral cocktails that will increase success rates from 50 percent to 75 percent. |
The Motley Fool
October 31, 2007
Brian Lawler |
The Next Hepatitis C Blockbuster? Never before have there been so many new drugs in development to treat Hepatitis C. Which companies have the compounds most likely to win this race? Investors, take note. |
The Motley Fool
October 19, 2007
Brian Lawler |
Schering's Gain Is Only a Mild Headache for Vertex Schering-Plough's strong phase 2 clinical results of its hepatitis C virus drug candidate send shares of competitor Vertex down. |
Chemistry World
December 9, 2009
Sarah Houlton |
New hep C breakthrough A drug being developed by Denmark's Santaris Pharma could provide a breakthrough in the treatment of hepatitis C, and positive results in a study on chimpanzees point to its potential to avoid drug resistance. |
The Motley Fool
September 11, 2007
Brian Lawler |
Score One for Pharmasset Shares of Pharmasset were up after the company announced impressive results for its Hepatitis C virus drug candidate R7128. Investors should continue to watch closely. |
The Motley Fool
October 26, 2007
Brian Lawler |
Another Prospect for Flamel The drug developer's good week continues with favorable news about a treatment for hepatitis C. Investors, take note. |
The Motley Fool
October 31, 2011
Brian Orelli |
Gunning for the Leaders Hepatitis C drugs take center stage. |
The Motley Fool
April 29, 2008
Brian Lawler |
So Pharmasset, So Good Early data hints at a promising hepatitis C treatment. |
The Motley Fool
April 25, 2008
Brian Lawler |
Vertex Silences the Critics New clinical study data bodes well for Vertex Pharmaceuticals' lead drug. |
The Motley Fool
June 29, 2007
Brian Orelli |
The Phase 2 Blues Drug developer Cytokinetics disappoints investors with failed clinical trials. |
The Motley Fool
January 8, 2008
Brian Lawler |
InterMune Goes Step by Step The company updates investors on the progress of its lead drug for hepatitis C. |
The Motley Fool
April 19, 2005
Charly Travers |
A Rising Star in Biotech Idenix is following a proven path to success: novel drug development. This is one biotech to keep on your watch list for the next year. |
The Motley Fool
April 3, 2008
Brian Lawler |
Will InterMune's Hepatitis C Drug Compete? InterMune announces positive data for its hepatitis C treatment drug. |
The Motley Fool
April 17, 2008
Brian Lawler |
The End for (Another) Hepatitis C Drug Candidate ViroPharma stops development of its compound after data showed it may hurt the liver. |
The Motley Fool
November 8, 2007
Brian Lawler |
Idenix Reels Itself In The small-cap drug developer cuts expenditures in the third quarter when sales of their hepatitis treatment don't materialize as quickly as hoped. Investors, take note. |
Chemistry World
January 11, 2012
Andrew Turley |
BMS spends $2.5 billion on antiviral firm The move will stock Bristol-Myers Squibb's pipeline with antivirals, most notably INX-189, a nucleotide polymerase inhibitor which is in Phase II trials for treating hepatitis C virus infection. |
The Motley Fool
July 24, 2007
Brian Lawler |
Discounting InterMune Shares of InterMune fall after analyst worries about one of its drugs. Investors looking to buy into the next blockbuster class of hepatitis C treatments on the cheap just got their chance. |
The Motley Fool
August 10, 2007
Brian Lawler |
ViroPharma Whacked by Data Shares of ViroPharma fall after safety issues come to light with one of its drugs. A phase 2 study of their hepatitis C antiviral medication has been halted, with only a slim chance of starting up again. |
The Motley Fool
May 17, 2010
Luke Timmerman |
Vertex Awaits Final Proof that Hepatitis C Drug Works For this drug researcher, the proof is in the telaprevir. |
The Motley Fool
May 27, 2005
Charly Travers |
Vertex's Cautious Optimism The company's innovative hepatitis C drug has made May a month to remember. Investors, take note. |
The Motley Fool
September 27, 2007
Brian Lawler |
ViroPharma's Good Bad News The prospects for ViroPharma's HCV-796 darkened significantly after the company reported troubling clinical results, however, there's still hope for the compound. Investors, take note. |
The Motley Fool
January 17, 2008
Brian Lawler |
The Good Times Roll for Pharmasset Shares ride high after the company releases positive clinical trial data. |
The Motley Fool
December 28, 2007
Brian Lawler |
Cubist's Cheap Call Option As a Christmas Eve present to itself, Cubist Pharmaceuticals follows through on its October option to purchase Illumigen. |
The Motley Fool
October 24, 2007
Brian Lawler |
Pharmasset on the Fast Track Hepatitis and HIV drug developer announced that its lead antihepatitis C compound has received fast-track status from the FDA. The decision is not fantastic news, but it could help. Investors, take note. |
The Motley Fool
September 7, 2010
Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
The Motley Fool
December 14, 2006
Brian Lawler |
Vertex: Coming Together Nicely If telaprevir continues to show anything like the 80%-90% rate of undetectable hepatitis C virus at end of its trials, Vertex shareholders won't be dealing with too many more down days. |
The Motley Fool
September 27, 2006
Brian Lawler |
One Step Forward for InterMune The company's lead drug will enter phase 1 trials, bringing potential good fortune to investors. |
American Family Physician
August 15, 2005
Ward & Kugelmas |
Using Pegylated Interferon and Ribavirin to Treat Patients with Chronic Hepatitis C New treatment regimens and advances in the management of side effects and toxicities have expanded the pool of patients who can be treated with pegylated interferon and ribavirin. |
The Motley Fool
June 15, 2007
Brian Lawler |
Idenix Gets Knocked Shares of Idenix drop slightly after the drug developer released clinical trial results this week. |
The Motley Fool
May 23, 2008
Brian Lawler |
Vertex's Lead Cut Down Schering-Plough is moving forward with its antiviral hepatitis C drug even faster than expected, much to Vertex's dismay. |
The Motley Fool
April 27, 2005
Charly Travers |
Vertex's Emerging Pipeline Early-stage drugs, including one for hepatitis C, are moving forward. For Vertex investors, the phase 2 trials will be the story to watch over the next two years. |
The Motley Fool
September 26, 2008
Brian Lawler |
Less Is More for Vertex The company's potential hepatitis C compound proves effective with fewer dosages. |
Chemistry World
December 3, 2013
Phillip Broadwith |
New wave of hepatitis C drugs hits US shore Johnson & Johnson's hepatitis C drug Olysio (simeprevir) has been approved by the US Food and Drug Administration. |
Chemistry World
June 12, 2014
Philli Broadwith |
Merck & Co bolsters hepatitis C pipeline with Idenix acquisition US drug firm Merck & Co has agreed to buy hepatitis C specialist Idenix for $3.85 billion. |
The Motley Fool
August 11, 2010
Brian Orelli |
Dang! This Drug Is Shining Brighter Vertex illuminates telaprevir's additional benefit in treating hepatitis C patients. |
The Motley Fool
July 27, 2011
Alexander Crawford |
Vertex Moving Closer to a Cure for Hepatitis C How do you think the treatment of hepatitis C will evolve? |
The Motley Fool
December 9, 2008
Brian Orelli |
Human Genome's Hep C Drug Is Halfway Home One trial down, one to go for Human Genome Sciences. |
The Motley Fool
January 24, 2008
Brian Lawler |
Vertex Under the Gun Vertex announces development plans for its lead drug. Investors, take note. |
The Motley Fool
May 2, 2007
Brian Lawler |
Progenics' Intriguing Study Results The development-stage drugmaker released clinical trial results for one of its compounds. Investors, take note. |
American Family Physician
February 15, 2003 |
Antiviral Drugs in the Immunocompetent Host: Part I. Treatment of Hepatitis, Cytomegalovirus, and Herpes Infections |
The Motley Fool
April 1, 2008
Brian Lawler |
Vertex Proves It ... Almost Vertex announces exciting clinical trial data that could get its anti-hepatitis C virus compound onto the market years earlier. |
The Motley Fool
October 16, 2007
Brian Orelli |
Not a Blockbuster -- Yet Merck gains marketing approval for its newest HIV drug. Investors, take note. |
The Motley Fool
June 27, 2008
Brian Lawler |
Difficult Obstacles for SciClone With all the new technologies and discoveries, some drugmakers are undoubtedly going to be left in the dust. SciClone Pharmaceuticals, with its lead drug Zadaxin, might be one such drugmaker. |
Nurse Practitioner
July 2010
Christine S. Brennan |
Overcoming barriers to new treatment options for hepatitis C This article reviews current guidelines for HCV treatment and proposes strategies to overcome potential barriers to state-of-the-art therapy. |
Nursing
December 2008
Susan Simmons Holcomb |
Caring for a patient with chronic hepatitis C Teach your patient about improved treatments that can help him deal with this potentially deadly infection. |
The Motley Fool
September 8, 2010
Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. |
The Motley Fool
January 30, 2009
Brian Orelli |
Mark Your Calendars: The Race Is On! In the last couple of weeks, both Schering-Plough and Vertex Pharmaceuticals have announced that their phase 3 hepatitis C drugs trials have finished enrolling patients. |
Chemistry World
October 31, 2008
Matt Wilkinson |
GSK Snaps up Hepatitis Drug Developer In a bid to strengthen its efforts to develop new hepatitis therapies, GSK has agreed to buy Genelabs Technologies in a deal worth $57 million. |
